Composition: IMAPRIL 5 MG — each film-coated tablet contains Imidapril Hydrochloride 5 mg.
IMAPRIL 10 MG: Each film-coated tablet contains Imidapril Hydrochloride 10 mg.
Usage: Treatment of high blood pressure (hypertension).
Category: Hypertensive / Cardiac Drugs
Therapeutic Category: Antihypertensive / ACE Inhibitor
SKU: Imidapril Hydrochloride Tablets
Categories: Pharmaceutical Exporter India, Pharmaceutical Formulations India, WHO GMP Certified Formulations
Imidapril Hydrochloride Tablets is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Imapril contains imidapril hydrochloride, a long-acting angiotensin-converting enzyme (ACE) inhibitor used for management of high blood pressure. Imidapril is a prodrug converted to the active metabolite imidaprilat. The supplied compositions identify two film-coated strengths: 5 mg and 10 mg.
Manufactured by: Healthy Life Pharma Pvt. Ltd. (WHO-GMP Certified)
Exported by: Healthy Inc (Star Export House)
| Product | Composition per tablet | Dosage form |
|---|---|---|
| IMAPRIL 5 MG | Imidapril Hydrochloride 5 mg | Film-coated tablet |
| IMAPRIL 10 MG | Imidapril Hydrochloride 10 mg | Film-coated tablet |
Generic name: Imidapril Hydrochloride. Therapeutic class: ACE inhibitor / antihypertensive. The 20 mg strength mentioned in the background description was not supported by the supplied product compositions. Pharmacopoeial standard, packaging, shelf life and CAS number should be checked against the approved product dossier.
Imidapril formulation requires appropriate control of moisture exposure, blending, compression, film coating and protective packaging. The specific dry-granulation process, humidity limits and aluminium-aluminium blister configuration described in marketing material should be verified against batch manufacturing records before being claimed for these products.
Product-specific testing should cover identity, assay, content uniformity, dissolution, related substances, packaging integrity and stability under the applicable approved specifications. Numerical acceptance limits and pharmacopoeial compliance should be confirmed from the certificate of analysis and registration documents.
Imidaprilat inhibits ACE, reducing formation of angiotensin II and aldosterone. This relaxes blood vessels and helps reduce blood pressure. Imidapril is used for essential hypertension in markets where it is approved. Additional indications, including diabetic nephropathy, are jurisdiction- and label-specific and must not be assumed for every formulation.
For third-party manufacturing or export enquiries, request current product-specific manufacturing licences, certificates of analysis, stability data, registration dossiers and available export documents. Availability of CTD/ACTD dossiers, COPP, free-sale certificates and destination-market approvals requires confirmation.
Q: Which strengths are listed?
A: IMAPRIL film-coated tablets containing 5 mg or 10 mg imidapril hydrochloride.
Q: Is imidapril an ACE inhibitor?
A: Yes. It lowers blood pressure by inhibiting the renin–angiotensin system.
Q: Can it cause a dry cough?
A: Yes. Persistent dry cough is a known ACE-inhibitor adverse effect.
Q: Is it safe in pregnancy?
A: No. ACE inhibitors can seriously harm a developing fetus; contact a clinician immediately if pregnancy is suspected or confirmed.
Use only as prescribed and according to the approved local product label. Dose and timing depend on blood pressure, kidney function, other medicines and clinical response. Some imidapril labels recommend taking the medicine before meals. Do not increase, stop or change treatment without medical advice.
Keep tablets in their original packaging and protect from excess moisture and heat. Follow the storage conditions on the approved pack label; keep out of reach of children.